Julien Grenier

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 409 citations · Full text

Advanced Biliary-tract Cancer, Gastrointestinal Oncology, Medicine +7

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Hervé Bonnefoi, Thomas Grellety, Olivier Trédan et al. · Annals of Oncology · 2016 · 275 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +8

Risk factors for brain relapse in patients with metastatic breast cancer

K. Slimane, Fabrice André, Suzette Delaloge et al. · Annals of Oncology · 2004 · 163 citations

Neuro-oncology, Metastatic Breast Cancer, Breast Oncology +11

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8